- ML348
-
- $39.00 / 2mg
-
2024-11-07
- CAS:899713-86-1
- Min. Order:
- Purity: 99.88%
- Supply Ability: 10g
|
| Product Name: | M348 | | Synonyms: | M348;ML348;N-[2-Chloro-5-(trifluoromethyl)phenyl]-4-(2-furanylcarbonyl)-1-piperazineacetamide;CS-2370;ML-348 (ML348);GNF-Pf-1127;ML 348;GNF-PF-1127;1-Piperazineacetamide, N-[2-chloro-5-(trifluoromethyl)phenyl]-4-(2-furanylcarbonyl)- | | CAS: | 899713-86-1 | | MF: | C18H17ClF3N3O3 | | MW: | 415.79 | | EINECS: | 809-791-4 | | Product Categories: | | | Mol File: | 899713-86-1.mol |  |
| Boiling point | 546.2±50.0 °C(Predicted) | | density | 1.422±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 25 mg/mL (60.13 mM; Need ultrasonic) | | form | Powder | | pka | 13.13±0.70(Predicted) | | color | White to off-white |
| Uses | ML348 is a reversible LYPLA1 inhibitor. It is 14-fold selective for LYPLA1 over LYPLA2 and demonstrates little activity against a panel of more than 20 other serine hydrolases. | | Biochem/physiol Actions | ML348 is a substrate-competitive, reversible and APT1-selective acyl-protein thioesterase (APT) inhibitor (IC50/Ki = 840 nM/300 nM against APT1; IC50 & Ki >10 μM against APT2). ML348 effectively inhibits cellular APT1 activity in cultures (by >95% in HEK293T & mouse T cells; 5 μM for 4 h) and in mice in vivo (by >90% in lung/heart/kidney and by ~50% in brain tissue 4 h post 50 mg/kg i.p. dosing) without affecting more than 15 cellular serine hydrolases and APT2. | | storage | Store at +4°C |
| | M348 Preparation Products And Raw materials |
|